Neurogene to Join BMO Genetic Medicines Summit

NEW YORK--Neurogene Inc. (NASDAQ: NGNE), a clinical-stage biotechnology firm dedicated to transforming the treatment landscape for rare neurological diseases through innovative genetic therapies, has announced its participation in the upcoming BMO 2024 Genetic Medicines Summit. Company representatives are scheduled to join the panel discussion titled “Gene Therapy in Rare Disease: Unmet Need + Lack of Alternatives = Commercial Viability?” and will also engage in meetings with investors. This event is set to take place on Tuesday, July 9 at 8:30 a.m. ET.

About Neurogene

Neurogene is committed to delivering transformative treatments that significantly improve the quality of life for patients and their families suffering from rare neurological disorders. The company is pioneering novel therapeutic approaches aimed at overcoming the challenges traditionally associated with gene therapy for central nervous system (CNS) conditions. By focusing on tailored delivery methods, Neurogene seeks to ensure that therapeutic agents reach the targeted tissues effectively. Additionally, the company prioritizes the development of products with maximized potency and purity to enhance safety and therapeutic efficacy.

Central to Neurogene's innovation is its proprietary EXACT transgene regulation platform technology. This advanced system is designed to deliver therapeutic levels of genes while minimizing the potential for transgene toxicity, which is a common issue with conventional gene therapies. This breakthrough technology enables the precise regulation of transgene expression, thus optimizing the therapeutic outcomes for patients.

The company's commitment to excellence is further demonstrated by its investment in a cutting-edge gene therapy manufacturing facility located in Houston, Texas. This facility is equipped to produce therapies under Current Good Manufacturing Practice (CGMP) standards, ensuring high quality and regulatory compliance. Notably, the production of NGN-401, one of Neurogene’s leading therapeutic candidates, has been conducted at this facility. This supports the pivotal clinical development activities required to advance NGN-401 toward potential market approval.

Neurogene's efforts are driven by a clear mission: to address the unmet medical needs of patients with rare CNS diseases, for whom few or no effective treatments currently exist. By harnessing the power of advanced genetic medicine, Neurogene aims to make significant strides in the field of neurological disease treatment, offering hope and improved outcomes to those affected by these debilitating conditions.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!